AI
Written with AI assistance•February 4, 2026•
AI
Generated IllustrationSwiss pharmaceutical giant Novartis experienced a stall in revenue growth in the final quarter of 2025, although full-year sales still climbed 8% to CHF 54.5 billion. The company has announced an increased dividend for shareholders but is forecasting slower, single-digit sales growth for the coming year.
"Novartis feels sales erosion in the final quarter due to copycats."
"The pace of revenue growth has slowed considerably after double-digit growth in each of the first two quarters."
The brakes have been slammed on the Novartis growth engine. After riding a wave of double-digit expansion earlier in the year, the Basel-based pharma titan hit a veritable wall in the final three months of 2025. Sales for the fourth quarter crawled to $13.3 billion, registering a meager 1% year-on-year increase. Even more alarming, when stripped of currency fluctuations, revenue actually contracted by 1% in real terms.
This sudden stagnation stands in stark contrast to the aggressive performance seen in the first half of the year. The culprit? A relentless erosion of sales caused by "copycats"—generic competitors that are chipping away at the market share of Novartis's blockbuster drugs. The era of easy growth appears to be over, forcing the company to confront a harsh new reality where every percentage point of gain must be fought for tooth and nail.
Despite the fourth-quarter stumble, the full 2025 financial picture remains undeniably robust. Novartis has delivered a colossal CHF 54.5 billion in total sales, marking a solid 8% climb over the previous year. This performance successfully met the management's ambitious forecast of high single-digit growth, proving that the Swiss giant's underlying fundamentals remain strong.
The bottom line tells an even more compelling story of efficiency and scale. Annual profit surged to a staggering CHF 14 billion, a significant leap from the just under CHF 12 billion recorded in 2024. While the year ended with a whimper, the overall financial health of the corporation is far from critical. Novartis has successfully navigated a turbulent global market to deliver massive value, banking billions in profit even as headwinds began to stiffen.
Cash remains king, and Novartis is ensuring its shareholders feel the weight of the royal treasury. In a bold move that defies the cautious end-of-year metrics, the company has announced a dividend hike to CHF 3.70 per share, up from CHF 3.50. This is a clear signal to the market: despite the slowing top-line growth, the company's cash generation engine is firing on all cylinders.
This payout strategy serves as a critical shield, protecting investor sentiment against the anxiety of the Q4 slowdown. By putting more cash directly into shareholders' pockets, Novartis is buying loyalty and patience. It is a confident assertion that while the market environment may be getting tougher, the company's ability to reward its owners remains compromised.
The hangover has officially begun. Looking ahead to 2026, Novartis management has stripped away the rose-colored glasses, issuing a forecast that is sobering at best. The company is bracing for a decline in core operating profit in the low single-digit range. Revenue growth targets have been slashed to the low single-digits, a far cry from the explosive expansion seen in early 2025.
The threat is structural and immediate: generic competition is cannibalizing sales of key legacy drugs. Coupled with the volatile political landscape—referenced by the impact of US policies on the industry—Novartis is entering a defensive phase. For the Swiss economy and the workforce in Basel, this signals a year of consolidation rather than conquest. The giant is not falling, but it is certainly slowing down to navigate a minefield of market saturation and regulatory pressure.